Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7849571rdf:typepubmed:Citationlld:pubmed
pubmed-article:7849571lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:7849571lifeskim:mentionsumls-concept:C0033692lld:lifeskim
pubmed-article:7849571lifeskim:mentionsumls-concept:C0033689lld:lifeskim
pubmed-article:7849571lifeskim:mentionsumls-concept:C2326566lld:lifeskim
pubmed-article:7849571lifeskim:mentionsumls-concept:C0205470lld:lifeskim
pubmed-article:7849571lifeskim:mentionsumls-concept:C1441547lld:lifeskim
pubmed-article:7849571lifeskim:mentionsumls-concept:C0486805lld:lifeskim
pubmed-article:7849571pubmed:issue5lld:pubmed
pubmed-article:7849571pubmed:dateCreated1995-3-14lld:pubmed
pubmed-article:7849571pubmed:abstractTextNeurocan is a brain-unique chondroitin sulfate proteoglycan (CSPG) whose expression and proteolytic cleavage are developmentally regulated. One of the proteolytic products (C-terminal half) is known to be a CSPG with a 150 kDa core glycoprotein (CSPG-150). To identify the N-terminal half of neurocan, we raised an anti-neurocan polyclonal antibody (PAb 291) using a synthetic peptide whose amino acid sequence matched a part of the N-terminal half of neurocan. Western blots showed that PAb 291 recognized two CSPGs, one with a 220 kDa core glycoprotein (CSPG-220, namely neurocan) and one with a 130 kDa core glycoprotein (CSPG-130) isolated from young rat brains. CSPG-130 was co-purified along with CSPG-220 by PAb 291-immunoaffinity column chromatography. The amino acid sequence of the N-terminus of the immunopurified CSPG-130 was exactly the same as the N-terminal sequence of CSPG-220. These results suggest that not only the C-terminal half (CSPG-150) but also the N-terminal half (CSPG-130) of CSPG-220 exists in a CSPG form in rat brain. Using PAb 291 and monoclonal antibody 1G2 (MAb 1G2) which recognizes CSPG-150 in addition to CSPG-220, we found that the contents of CSPG-130 and CSPG-150 in the rat brain reached maximum levels around the time of birth. Both CSPG-130 and 150 were observed, while CSPG-220 was hardly detectable in extracts from the adult rat brain. Immunohistochemical investigation showed that the PAb 291 antigen had a similar distribution pattern to the MAb 1G2 antigen.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:7849571pubmed:languageenglld:pubmed
pubmed-article:7849571pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7849571pubmed:citationSubsetIMlld:pubmed
pubmed-article:7849571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7849571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7849571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7849571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7849571pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7849571pubmed:statusMEDLINElld:pubmed
pubmed-article:7849571pubmed:monthNovlld:pubmed
pubmed-article:7849571pubmed:issn0197-0186lld:pubmed
pubmed-article:7849571pubmed:authorpubmed-author:WatanabeEElld:pubmed
pubmed-article:7849571pubmed:authorpubmed-author:OohiraAAlld:pubmed
pubmed-article:7849571pubmed:authorpubmed-author:MatsuiFFlld:pubmed
pubmed-article:7849571pubmed:issnTypePrintlld:pubmed
pubmed-article:7849571pubmed:volume25lld:pubmed
pubmed-article:7849571pubmed:ownerNLMlld:pubmed
pubmed-article:7849571pubmed:authorsCompleteYlld:pubmed
pubmed-article:7849571pubmed:pagination425-31lld:pubmed
pubmed-article:7849571pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:meshHeadingpubmed-meshheading:7849571-...lld:pubmed
pubmed-article:7849571pubmed:year1994lld:pubmed
pubmed-article:7849571pubmed:articleTitleImmunological identification of two proteoglycan fragments derived from neurocan, a brain-specific chondroitin sulfate proteoglycan.lld:pubmed
pubmed-article:7849571pubmed:affiliationDepartment of Perinatology, Institute for Developmental Research, Aichi, Japan.lld:pubmed
pubmed-article:7849571pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7849571pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:7849571pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7849571lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7849571lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7849571lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7849571lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7849571lld:pubmed